A revolution in the treatment of rheumatoid arthritis occurred when drugs aimed at inhibiting pro-inflammatory cytokines were introduced, especially those targeting tumor necrosis factor alpha (TNF-α), which is involved in most of the studied inflammatory processes. The gene discussed is TNF; the disease is rheumatoid arthritis.